Sun Kang, Wang Liang, Zhang Yanyun
Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Cell Mol Immunol. 2006 Jun;3(3):197-203.
Dendritic cells (DCs) are the most potent professional antigen-presenting cells, and capable of stimulating naïve T cells and driving primary immune responses. DCs are poised to capture antigen, migrate to draining lymphoid organs, and after a process of maturation, select antigen-specific lymphocytes to which they present the processed antigen, thereby inducing immune responses. The development of protocols for the ex vivo generation of DCs may provide a rationale for designing and developing DC-based vaccination for the treatment of tumors. There are now several strategies being applied to upload antigens to DCs and manipulate DC vaccines. DC vaccines are able to induce therapeutic and protective antitumor immunity. Numerous studies indicated that hepatocellular carcinoma (HCC) immunotherapies utilizing DC-presenting tumor-associated antigens could stimulate an antitumour T cell response leading to clinical benefit without any significant toxicity. DC-based tumor vaccines have become a novel immunoadjuvant therapy for HCC.
树突状细胞（DCs）是最强大的专职抗原呈递细胞，能够刺激初始T细胞并驱动初级免疫反应。DCs随时准备捕获抗原，迁移至引流淋巴器官，并在经历成熟过程后，选择它们向其呈递加工后的抗原的抗原特异性淋巴细胞，从而诱导免疫反应。用于离体生成DCs的方案的开发可能为设计和开发基于DC的肿瘤疫苗治疗提供理论依据。目前有几种策略被应用于将抗原加载到DCs上并操控DC疫苗。DC疫苗能够诱导治疗性和保护性抗肿瘤免疫。大量研究表明，利用呈递肿瘤相关抗原的DCs进行的肝细胞癌（HCC）免疫疗法可刺激抗肿瘤T细胞反应，从而带来临床益处且无任何明显毒性。基于DC的肿瘤疫苗已成为一种用于HCC的新型免疫辅助疗法。
